Send to printer »

Insight & Intelligence™ : Sep 23, 2013

Top 40 Molecular Millionaires

Who’s stocking up on biopharma stock?

Following is a list of 40 executives of publicly traded biopharma drug developers and tools/technology companies, ranked by the total value of their shares of common stock as stated on the companies’ proxy statements or Form 20-F statements. Each executive is listed with their title and company, the total value of their shares of common stock, the number of shares of common stock (by category where available), and the closing share price of their company’s stock as of the “record date” for determining shareholders entitled to notice of, and to vote at, their company’s annual meeting, with footnotes where applicable.

Unlike the first edition of this list last year (see “Top 20 Molecular Millionaires,” published in GEN October 2, 2012), all categories of shares of common stock were listed—not only the value of their shares of common stock as of the day they were tallied and recorded in filings, but shares of common stock which were exercisable or became so within a set period of time (typically 60 days) from the record date. The change reflects the fact numerous companies recorded the total number of shares of common stock for their largest shareholders—with explanations about multiple common stock categories in footnotes of the proxies or 20-F forms—in order to present a more complete picture of who owns what percentage of the companies’ stock. The change also explains why the top three on this list could better be described as molecular billionaires.

The results showed the wealthiest molecular millionaires were officers, directors, former officers and directors, or investors of mature biotechs—typically those with products on the market, and the profits that follow. Several companies in that category could boast of having multiple executives, directors, or investors on this year’s list: Regeneron Pharmaceuticals led biotechs—and all companies, for that matter—with seven, followed by Vertex Pharmaceuticals (four), Bio-Rad Laboratories and Danaher (three each), and Bristol-Myers Squibb, Life Technologies, and Mettler Toledo (two each).

The results reflect how good a year 2012 was for Regeneron and Vertex. In its proxy report, Regeneron noted the company overachieved its goals for last year, among them continued successful commercialization of Eylea (aflibercept) injection, including launch following FDA approval for a new macular edema indication; and FDA approval of Zaltrap (ziv-aflibercept) injection for IV infusion for use with Folfiri for metastatic colorectal cancer. Vertex launched Kalydeco for cystic fibrosis shortly after it gained FDA approval on August 31, 2012 and quickly racked up $171.6 million in sales, a figure expected to rise significantly this year.

Big pharmas have only a small presence on this list, with only five executives and/or investors from four such companies appearing. Ranking highest among big pharmas, at No. 14, was not a current pharma exec but a retired chairman. The CEOs of two other pharma giants—Joseph Jimenez of Novartis, and Ian C. Read of Pfizer—narrowly missed the top 40.

#40. William P. Sullivan

President and CEO, Agilent Technologies

Total value of all shares: $41,064,949

368,783 shares of common stock; 634,269 shares subject to options exercisable March 1, as of December 31, 20121

Closing price on December 31, 2012: $40.94

#39. David F. Hoffmeister

CFO, Life Technologies2

Total value of all shares: $41,442,973

691,177 shares of common stock as of March 63

Closing price on March 6: $59.96

#38. Ian F. Smith

EVP and CFO, Vertex Pharmaceuticals

Total value of all shares: $41,800,057

795,434 shares of common stock as of March 114

Closing price on March 11: $52.55

#37. Charles A. Baker

Director, Regeneron Pharmaceuticals

Total value of all shares: $47,806,2035

161,974 shares of common stock and 62,384 Class A shares as of April 176,7

Closing price on April 17: $213.08

#36. Peter Mueller, Ph.D.

EVP, Global Research and Development, and CSO, Vertex Pharmaceuticals

Total value of all shares: $52,426,560

997,651 shares of common stock as of April 178

Closing price on April 17: $52.55

#35. George L. Sing

Director, Regeneron Pharmaceuticals

Total value of all shares: $53,434,498

250,772 shares of common stock as of April 179

Closing price on April 17: $213.08

#34. Marc N. Casper

President and CEO, Thermo Fisher Scientific

Total value of all shares: $56,122,022

924,885 shares of common stock as of February 1110

Closing price as of February 11: $60.68

#33. Robert J. Coury

Executive Chairman of the Board, Mylan

Total value of all shares: $57,074,91111

1,087,411 shares of common stock; 879,333 shares with options exercisable and restricted shares vesting within 60 days as of March 26

Closing price on March 26: $29.02

#32. Murray A. Goldberg

SVP, Finance and Administration, CFO, and Secretary, Regeneron Pharmaceuticals

Total value of all shares: $62,385,136

292,778 shares of common stock as of April 1712

Closing price on April 17: $213.08

#31. Robert F. Friel

Chairman and CEO, PerkinElmer

Total value of all shares: $63,378,82913

516,849 shares of common stock; 1,340,134 shares acquirable within 60 days as of February 1514

Closing price on February 15: $34.13

Following is a list of 40 executives of publicly traded biopharma drug developers and tools/technology companies, ranked by the total value of their shares of common stock as stated on the companies’ proxy statements or Form 20-F statements. Each executive is listed with their title and company, the total value of their shares of common stock, the number of shares of common stock (by category where available), and the closing share price of their company’s stock as of the “record date” for determining shareholders entitled to notice of, and to vote at, their company’s annual meeting, with footnotes where applicable.

Unlike the first edition of this list last year (see “Top 20 Molecular Millionaires,” published in GEN October 2, 2012), all categories of shares of common stock were listed—not only the value of their shares of common stock as of the day they were tallied and recorded in filings, but shares of common stock which were exercisable or became so within a set period of time (typically 60 days) from the record date. The change reflects the fact numerous companies recorded the total number of shares of common stock for their largest shareholders—with explanations about multiple common stock categories in footnotes of the proxies or 20-F forms—in order to present a more complete picture of who owns what percentage of the companies’ stock. The change also explains why the top three on this list could better be described as molecular billionaires.

The results showed the wealthiest molecular millionaires were officers, directors, former officers and directors, or investors of mature biotechs—typically those with products on the market, and the profits that follow. Several companies in that category could boast of having multiple executives, directors, or investors on this year’s list: Regeneron Pharmaceuticals led biotechs—and all companies, for that matter—with seven, followed by Vertex Pharmaceuticals (four), Bio-Rad Laboratories and Danaher (three each), and Bristol-Myers Squibb, Life Technologies, and Mettler Toledo (two each).

The results reflect how good a year 2012 was for Regeneron and Vertex. In its proxy report, Regeneron noted the company overachieved its goals for last year, among them continued successful commercialization of Eylea (aflibercept) injection, including launch following FDA approval for a new macular edema indication; and FDA approval of Zaltrap (ziv-aflibercept) injection for IV infusion for use with Folfiri for metastatic colorectal cancer. Vertex launched Kalydeco for cystic fibrosis shortly after it gained FDA approval on August 31, 2012 and quickly racked up $171.6 million in sales, a figure expected to rise significantly this year.

Big pharmas have only a small presence on this list, with only five executives and/or investors from four such companies appearing. Ranking highest among big pharmas, at No. 14, was not a current pharma exec but a retired chairman. The CEOs of two other pharma giants—Joseph Jimenez of Novartis, and Ian C. Read of Pfizer—narrowly missed the top 40.

#30. John C. Lechleiter, Ph.D.

Chairman of the Board, President, and CEO, Eli Lilly

Total value of all shares: $64,099,59915

653,571 shares of common stock16; 468,775 options exercisable/restricted stock units distributable within 60 days; 58,778 restricted stock units not distributable within 60 days

Closing price: $54.27 as of February 22

#29. Neil Stahl, Ph.D.

SVP, Research & Development, Regeneron Pharmaceuticals

Total value of all shares: $63,345,275

297,284 shares of common stock as of April 1717

Closing price on April 17: $213.08

#28. Kenneth C. Frazier

Chairman, President, and CEO, Merck & Co

Total value of all shares: $64,254,29718

242,561 shares of common stock19 and 1,261,167 in options/stock units that were exercisable/distributable within 60 days as of February 28

Closing price on February 28: $42.73

#27. Vincent A. Forlenza

Chairman, CEO, and President, Becton, Dickinson

Total value of all shares: $68,455,65320

79,199 shares of common stock21 and 813,662 shares that may be acquired within 60 days22, as of December 1, 2012

Closing price on December 1, 2012: $76.67 on November 30 (no trading on December 1)

#26. Robert A. Bradway

Chairman of the Board, President and CEO, Amgen

Total value of all shares: $77,802,61523

436,728 shares of common stock and 366,935 shares acquirable within 60 days of March 2524

Closing price on March 25: $96.81

#25. Matthew W. Emmens

Former Chairman, CEO and President, Vertex Pharmaceuticals

Total value of all shares: $78,128,607

1,486,748 shares of common stock as of March 1125

Closing price on March 11: $52.55

#24. Peter D. Meldrum

President and CEO, Myriad Genetics

Total value of all shares: $78,773,55026

1,871,995 shares of common stock as of September 1, 201227

Closing price on September 1, 2012: $42.08 on August 31, 2012 (no trading on September 1, 2012)

#23. Howard Solomon

Chairman, President, and CEO, Forest Laboratories

Total value of all shares: $98,096,120

2,424,521 shares of common stock as of June 2428

Closing price on June 24: $40.46

#22. Gregory T. Lucier

Chairman and CEO, Life Technologies2

Total value of all shares: $107,336,914

1,790,142 shares of common stock as of March 629

Closing price on March 6: $59.96

21. Olivier T. Filliol

President and CEO, Mettler Toledo

Total value of all shares: $108,178,68130

16,279 direct shares of common stock and 496,562 indirect shares of common stock subject to stock options that were exercisable within 60 days, as of March 4

Closing price on March 4: $210.94

Following is a list of 40 executives of publicly traded biopharma drug developers and tools/technology companies, ranked by the total value of their shares of common stock as stated on the companies’ proxy statements or Form 20-F statements. Each executive is listed with their title and company, the total value of their shares of common stock, the number of shares of common stock (by category where available), and the closing share price of their company’s stock as of the “record date” for determining shareholders entitled to notice of, and to vote at, their company’s annual meeting, with footnotes where applicable.

Unlike the first edition of this list last year (see “Top 20 Molecular Millionaires,” published in GEN October 2, 2012), all categories of shares of common stock were listed—not only the value of their shares of common stock as of the day they were tallied and recorded in filings, but shares of common stock which were exercisable or became so within a set period of time (typically 60 days) from the record date. The change reflects the fact numerous companies recorded the total number of shares of common stock for their largest shareholders—with explanations about multiple common stock categories in footnotes of the proxies or 20-F forms—in order to present a more complete picture of who owns what percentage of the companies’ stock. The change also explains why the top three on this list could better be described as molecular billionaires.

The results showed the wealthiest molecular millionaires were officers, directors, former officers and directors, or investors of mature biotechs—typically those with products on the market, and the profits that follow. Several companies in that category could boast of having multiple executives, directors, or investors on this year’s list: Regeneron Pharmaceuticals led biotechs—and all companies, for that matter—with seven, followed by Vertex Pharmaceuticals (four), Bio-Rad Laboratories and Danaher (three each), and Bristol-Myers Squibb, Life Technologies, and Mettler Toledo (two each).

The results reflect how good a year 2012 was for Regeneron and Vertex. In its proxy report, Regeneron noted the company overachieved its goals for last year, among them continued successful commercialization of Eylea (aflibercept) injection, including launch following FDA approval for a new macular edema indication; and FDA approval of Zaltrap (ziv-aflibercept) injection for IV infusion for use with Folfiri for metastatic colorectal cancer. Vertex launched Kalydeco for cystic fibrosis shortly after it gained FDA approval on August 31, 2012 and quickly racked up $171.6 million in sales, a figure expected to rise significantly this year.

Big pharmas have only a small presence on this list, with only five executives and/or investors from four such companies appearing. Ranking highest among big pharmas, at No. 14, was not a current pharma exec but a retired chairman. The CEOs of two other pharma giants—Joseph Jimenez of Novartis, and Ian C. Read of Pfizer—narrowly missed the top 40.

#20. Jay T. Flatley

President, CEO, and Director, Illumina

Total value of all shares: $123,874,22031

327,921 shares of common stock32 and options for 1,943,750 shares exercisable within 60 days of April 133, as of April 2

Closing price on April 2: $54.53

#19. Robert F. Spoerry

Chairman of the Board of Directors, Mettler Toledo34

Total value of all shares: $131,472,99635

370,193 direct shares of common stock and 253,079 indirect shares of common stock subject to stock options that are exercisable within 60 days, as of March 436

Closing price on March 4: $210.94

#18. James M. Cornelius

Nonexecutive Chairman; CEO, 2008–10, Bristol-Myers Squibb

Total value of shares of common stock: $132,638,30637

2,200,804 shares of common stock38; 1,245,996 shares underlying options or stock units39; and 23,590 shares of common stock underlying deferred share units40 as of March 12

Closing price as of March 12: $38.22

#17. Joshua Boger, Ph.D.

Founder and Director, Vertex Pharmaceuticals41

Total value of all shares: $132,970,891

2,530,369 shares of common stock as of March 1142

Closing price on March 11: $52.55

#16. Lamberto Andreotti

CEO, Bristol-Myers Squibb

Total value of shares of common stock: $140,883,35343

2,127,292 shares of common stock44 and 1,558,824 shares underlying options or stock units39 as of March 12

Closing price as of March 12: $38.22

#15. H. Lawrence Culp, Jr.

President and CEO, Danaher

Total value of all shares: $180,150,012

2,908,460 shares of common stock as of March 845

Closing price on March 8: $61.94

#14. William C. Weldon

Retired Chairman, Johnson & Johnson46

Total value of all shares: $260,500,76547

386,591 shares of common stock48; and 3,052,363 shares of common stock Underlying Options or Stock Units49 as of February 26

Closing price on February 26: $75.75

#13. Robert J. Hugin

Chairman and CEO, Celgene

Total value of all shares: $267,201,601

2,202,090 shares of common stock as of April 1750

Closing price on April 17: $121.34

#12. David E.I. Pyott

Chairman of the Board and CEO, Allergan

Total value of all shares: $267,333,70851

234,157 shares of common stock; 2,164,100 shares that he had rights to acquire within 60 days of March 652

Closing price on March 6: $111.47

#11. Leonard Bell, M.D.

CEO, Alexion Pharmaceuticals

Total value of all shares: $330,186,815

3,601,907 shares of common stock as of March 1153

Closing price on March 11: $91.67

Following is a list of 40 executives of publicly traded biopharma drug developers and tools/technology companies, ranked by the total value of their shares of common stock as stated on the companies’ proxy statements or Form 20-F statements. Each executive is listed with their title and company, the total value of their shares of common stock, the number of shares of common stock (by category where available), and the closing share price of their company’s stock as of the “record date” for determining shareholders entitled to notice of, and to vote at, their company’s annual meeting, with footnotes where applicable.

Unlike the first edition of this list last year (see “Top 20 Molecular Millionaires,” published in GEN October 2, 2012), all categories of shares of common stock were listed—not only the value of their shares of common stock as of the day they were tallied and recorded in filings, but shares of common stock which were exercisable or became so within a set period of time (typically 60 days) from the record date. The change reflects the fact numerous companies recorded the total number of shares of common stock for their largest shareholders—with explanations about multiple common stock categories in footnotes of the proxies or 20-F forms—in order to present a more complete picture of who owns what percentage of the companies’ stock. The change also explains why the top three on this list could better be described as molecular billionaires.

The results showed the wealthiest molecular millionaires were officers, directors, former officers and directors, or investors of mature biotechs—typically those with products on the market, and the profits that follow. Several companies in that category could boast of having multiple executives, directors, or investors on this year’s list: Regeneron Pharmaceuticals led biotechs—and all companies, for that matter—with seven, followed by Vertex Pharmaceuticals (four), Bio-Rad Laboratories and Danaher (three each), and Bristol-Myers Squibb, Life Technologies, and Mettler Toledo (two each).

The results reflect how good a year 2012 was for Regeneron and Vertex. In its proxy report, Regeneron noted the company overachieved its goals for last year, among them continued successful commercialization of Eylea (aflibercept) injection, including launch following FDA approval for a new macular edema indication; and FDA approval of Zaltrap (ziv-aflibercept) injection for IV infusion for use with Folfiri for metastatic colorectal cancer. Vertex launched Kalydeco for cystic fibrosis shortly after it gained FDA approval on August 31, 2012 and quickly racked up $171.6 million in sales, a figure expected to rise significantly this year.

Big pharmas have only a small presence on this list, with only five executives and/or investors from four such companies appearing. Ranking highest among big pharmas, at No. 14, was not a current pharma exec but a retired chairman. The CEOs of two other pharma giants—Joseph Jimenez of Novartis, and Ian C. Read of Pfizer—narrowly missed the top 40.

#10. John C. Martin

Chairman and CEO, Gilead Sciences

Total value of all shares: $598,523,647

14,010,385 shares of common stock as of February 2854

Closing price on February 28: $42.72

#9. P. Roy Vagelos, M.D.

Chairman of the Board of Directors, Regeneron Pharmaceuticals

Total value of all shares: $675,793,660

3,171,549 shares of common stock as of April 1755

Closing price on April 17: $213.08

#8. Philip Frost

Chaiman, Teva Pharmaceutical Industries

Total value of all shares: $544,686,197

14,587,204 shares as of December 31, 2012

Closing price on December 31: $37.34

#7. Steven Schwartz

Shareholder, Bio-Rad Laboratories56

Total value of all shares: $547,096,70357

364,494 Class A shares of common stock58 and 4,076,226 Class B shares of common stock59 as of February 28

Closing price on February 28: $123.20

#6. George D. Yancopoulos, M.D., Ph.D.

Chief Scientific Officer and President, Regeneron Laboratories, Regeneron Pharmaceuticals

Total value of all shares: $580,126,28160

2,679,825 shares of common stock61 and 42,750 Class A shares as of April 1762

Closing price on April 17: $213.08

#5. Norman Schwartz

President, CEO, and Chairman, Bio-Rad Laboratories56

Total value of all shares: $607,265,12063

411,252 Class A shares of common stock64 and 4,517,848 Class B shares of common stock65 as of February 28

Closing price on February 28: $123.20

#4. Alice N. Schwartz

Co-founder, Bio-Rad Laboratories

Total value of all shares: $912,592,05066

2,807,223 Class A shares of common stock67 and 4,600,054 Class B shares of common stock68 as of February 28

Closing price on February 28: $123.20

#3. Leonard S. Schleifer, M.D., Ph.D.

President and CEO, Regeneron Pharmaceuticals

Total value of all shares: $1,130,975,37069

3,754,685 shares of common stock70 and 1,733,065 Class A shares71,72 as of April 17

Closing price on April 17: $213.08

#2. Steven M. Rales

Co-founder and Chairman of the Board, Danaher

Total value of all shares: $2,720,905,770

43,928,088 shares of common stock as of March 873,74

Closing price on March 8: $61.94

#1. Mitchell P. Rales

Co-founder and Chairman of the Executive Committee, Danaher

Total value of all shares: $2,974,281,127

48,018,746 shares of common stock as of March 873,75

Closing price on March 8: $61.94